Please select the option that best describes you:
Would you give a fit <40 year old with T3N1b low risk Stage IIIB colon adenocarcinoma 6 months of adjuvant chemo or feel comfortable limiting to 3 months of CAPOX?
Does the patient's young age affect your decision when applying data from the IDEA collaboration?
Answer from: Medical Oncologist at Academic Institution
For T3N1 disease, 3 months of therapy with oxaliplatin and fluoro-pyrimidine is non-inferior to 6 months. Statistically equivalent with an upper limit of 95% CI <1.12. Furthermore, on retrospective subset analysis (choice of FOLFOX or CapeOX not randomized), 3 months of CapeOX was superior to 6 m...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
IDEA confirmed that 3 months of oxaliplatin-based adjuvant therapy is adequate for low-risk stage 3 patients, and hence, 3 months of CAPOX or FOLFOX is appropriate.